Would have thought the article about the comparability in terms of safety to Epogen from the New England journal of medicine would have helped today. As well as the positive article from Seeking Alpha today.
My sources seem to think the New England Journal article was slanted towards Epogen.. Claims some of the article isn't fact. Believe's Amgen lobbying efforts effected some of the news (misleading) when comparing Omentys against Epogen.. Source believes Omontys is doing well at Fresenius clinics and suggests this stock should be making money soon..